Status:
UNKNOWN
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Lead Sponsor:
Ge Zheng
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Acute myeloid leukemia (AML) is highly heterogeneous, the efficacy of the individual varies greatly, and the risk of recurrence is high. A large number of newly diagnosed AML patients cannot achieve c...
Detailed Description
This study is aimed to observe the efficacy and safety of the Chidamide Plus Cladribine regimen in treating patients with refractory or relapsed AML. Patients must provide written informed consent and...
Eligibility Criteria
Inclusion
- Age greater than 18 years old and less than 75 years old;
- Clinical diagnosis of Relapsed/Refractory AML (non-APL);
- ECOG performance status score 0-3;
- Participant has the ability to understand and willingness to sign a written consent document.
Exclusion
- Pregnancy or nursing
- Uncontrolled significant cardiac disorder
- Psychiatric disorder may interfere with his / her compliance with the study protocol
- Known history of intolerance or allergy to any component of the research regimen
- Any condition not suitable for the trial as judged by the study investigator.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05330364
Start Date
June 1 2021
End Date
June 1 2023
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University
Nanjing, Jiangsu, China, 210009